



**UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office**

Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
087817,547	03/27/97	ADERMANN	K 07856-0007

JONES & ASKEW  
191 PEACHTREE STREET 37TH FLOOR  
ATLANTA GA 30303-1769

18M2/1231

EXAMINER
HARLE, J

ART UNIT	PAPER NUMBER
1811	#4

DATE MAILED:

12/31/97

**Please find below and/or attached an Office communication concerning this application or proceeding.**

**Commissioner of Patents and Trademarks**



UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office  
COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
08/817,547	03/27/97	Andermann, et al.	07856-0007

b

b

EXAMINER	
Jennifer Harle	
ART UNIT	PAPER NUMBER
1811	3

b

b

DATE MAILED:


Please find below a communication from the EXAMINER in charge of this application

Commissioner of Patents

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

There are many examples in the specification and claims where the sequences are not properly identified with the appropriate SEQ ID No. For example, as set forth in new claim 6, hPTH1-10, is a peptide sequence which is encompassed by the definitions of the sequence disclosure which is set forth in 37 CFR 1.821-.825. Additional pages include 3-5. It is noted that "new claim 6" was filed as "new claim 7", however, there is no claim 6 and claim 7 was renumber pursuant to R.126. Additionally, examiner notes that the numbers in parenthesis appear to correspond to the sequence numbers in the listing. However, please clarify that these numbers are the sequence identification numbers. These pages should have the appropriate SEQ ID No. following the sequences as per the requirement in 37 CFR 1.821-.825.

Additionally, applicant needs to file a disk encompassing the listing. See attached Notice To comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures

  
CECILIA J. TSANG  
SUPERVISORY PATENT EXAMINER  
GROUP 1000

APPLICANT IS GIVEN ONE MONTH FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Any inquiry concerning this communication should be directed to Examiner Jennifer Harle, Art Unit 1811, whose telephone number is (703) 305-4508.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.